PhaseBio Pharmaceuticals Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PhaseBio Pharmaceuticals stock.
View analyst ratings for PhaseBio Pharmaceuticals or view top-rated stocks.

3 Wall Street analysts have issued 12-month price objectives for PhaseBio Pharmaceuticals' stock. Their PHAS stock forecasts range from $10.00 to $15.00. On average, they predict PhaseBio Pharmaceuticals' share price to reach $12.50 in the next year. This suggests a possible upside of 1,801.7% from the stock's current price.
View analysts' price targets for PhaseBio Pharmaceuticals or view top-rated stocks among Wall Street analysts.

PhaseBio Pharmaceuticals' stock was trading at $2.61 at the start of the year. Since then, PHAS shares have decreased by 74.8% and is now trading at $0.6573.
View the best growth stocks for 2022 here.

PhaseBio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for PhaseBio Pharmaceuticals.

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) announced its quarterly earnings data on Monday, May, 16th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.67) by $0.44. The firm had revenue of $0.12 million for the quarter, compared to the consensus estimate of $5.83 million.
View PhaseBio Pharmaceuticals' earnings history.

Some companies that are related to PhaseBio Pharmaceuticals include Longeveron (LGVN), ProMetic Life Sciences (PFSCF), Satsuma Pharmaceuticals (STSA), Enochian Biosciences (ENOB), MediciNova (MNOV), Nanobiotix (NBTX), Endo International (ENDP), CytomX Therapeutics (CTMX), Otonomy (OTIC), Actinium Pharmaceuticals (ATNM), Actinium Pharmaceuticals (ATNM), Applied Molecular Transport (AMTI), Praxis Precision Medicines (PRAX), ContraFect (CFRX) and Homology Medicines (FIXX).
View all of PHAS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Sorrento Therapeutics (SRNE), Amarin (AMRN), Vaxart (VXRT) and Agile Therapeutics (AGRX).

(PHAS) raised $66 million in an initial public offering (IPO) on Thursday, October 18th 2018. The company issued 5,000,000 shares at $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.

PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."

Shares of PHAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PHAS stock can currently be purchased for approximately $0.66.

PhaseBio Pharmaceuticals (NASDAQ:PHAS) has a market capitalization of $32.00 million and generates $10.83 million in revenue each year. The company earns $-131.07 million in net income (profit) each year or ($2.39) on an earnings per share basis.

PhaseBio Pharmaceuticals employs 60 workers across the globe.

PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The official website for PhaseBio Pharmaceuticals is www.phasebio.com. The company can be reached via phone at (610) 981-6500 or via email at [email protected].